News
On Wednesday, the FDA raised concerns about life-threatening hematologic malignancies in patients treated with Bluebird Bio Inc’s (NASDAQ:BLUE) Skysona (elivaldogene autotemcel), a gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback